BSE - Delayed Quote INR
Jenburkt Pharmaceuticals Limited (JENBURPH.BO)
1,060.15
-19.15
(-1.77%)
At close: 3:25:20 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,491,535
1,416,334
1,361,405
1,237,317
1,088,684
Cost of Revenue
306,892
311,370
338,055
320,627
304,430
Gross Profit
1,184,643
1,104,964
1,023,350
916,690
784,254
Operating Expense
816,284
797,131
742,221
663,105
606,169
Operating Income
368,359
307,833
281,129
253,585
178,085
Net Non Operating Interest Income Expense
37,273
38,561
36,529
39,370
35,788
Pretax Income
424,623
351,759
328,647
298,709
216,417
Tax Provision
110,564
91,986
82,577
75,737
51,393
Net Income Common Stockholders
314,059
259,773
246,070
222,972
165,024
Diluted NI Available to Com Stockholders
314,059
259,773
246,070
222,972
165,024
Basic EPS
71.16
58.86
53.90
48.58
35.96
Diluted EPS
71.16
58.86
53.90
48.58
35.96
Basic Average Shares
4,413.30
4,413.30
4,565.67
4,589.38
4,589.38
Diluted Average Shares
4,413.30
4,413.30
4,565.67
4,589.38
4,589.38
Rent Expense Supplemental
--
2,846
1,725
1,853
1,660
Total Expenses
1,123,176
1,108,501
1,080,276
983,732
910,599
Net Income from Continuing & Discontinued Operation
314,059
259,773
246,070
222,972
165,024
Normalized Income
312,966.58
258,713.25
244,741.27
220,683.61
164,929.87
Interest Income
--
41,267
40,199
43,714
40,525
Interest Expense
3,587
2,299
2,997
3,480
4,241
Net Interest Income
37,273
38,561
36,529
39,370
35,788
EBIT
428,210
354,058
331,644
302,189
220,658
EBITDA
453,759
377,453
354,235
321,175
241,012
Reconciled Cost of Revenue
306,892
311,370
338,055
320,627
304,430
Reconciled Depreciation
25,549
23,395
22,591
18,986
20,354
Net Income from Continuing Operation Net Minority Interest
314,059
259,773
246,070
222,972
165,024
Total Unusual Items Excluding Goodwill
1,477
1,477
1,811
2,982
127
Total Unusual Items
1,477
1,477
1,811
2,982
127
Normalized EBITDA
452,282
375,976
352,424
318,193
240,885
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
384.58
417.25
482.27
693.61
32.87
3/31/2021 - 12/30/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade